At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.


French German Italian Portuguese Russian

Treatment Study for Recurrent Platinum-Resistant Ovarian Cancer

Clinical Trial Title: 
The OVAL study: A randomized, controlled, double-arm, double blind, multi-center study of ofranergene obadenovec (VB-111) combined with paclitaxel vs. paclitaxel combined with placebo for the treatment of recurrent platinum-resistant ovarian cancer.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Summer B. Dewdney, MD
Clinical Trial Protocol Description: 

The purpose of this phase 3, randomized, multi-center study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with recurrent platinum-resistant ovarian cancer.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are a female patient at least 18 years of age.
  • Have histologically confirmed epithelial ovarian cancer and documented disease.
  • Have platinum-resistant disease
  • Have disease that is measurable according to RECIST 1.1 and require chemotherapy treatment.

You will be excluded from the study if any of the following criteria apply to you:

  • Have non-epithelial tumors (Carcino-sarcomas are excluded).
  • Have ovarian tumors with low malignant potential (i.e. borderline tumors) clear cell carcinomas, grade 1 serous tumors or mucinous tumors.
  • Have a history of other clinically active malignancy within 5 years of enrollment, except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal-cell carcinoma, adequately controlled, non-metastatic squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast.
  • Have had previous ovarian cancer treatment with >5 anticancer regimens.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Gynecologic Cancers
Contact Email: 
Contact Phone: 
(312) CANCER-1
Contact Name: 
Rush Cancer Center Clinical Trials Office